10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-IL-18 Reference Antibody (Camoteskimab)

Recombinant Antibody
Catalog # APR10064

Specification

Anti-IL-18 Reference Antibody (Camoteskimab) - Product Information

Application	**FC, E, FTA**
Primary Accession	Q14116
Reactivity	**Cynomolgus, Human**
Clonality	**Monoclonal**
Isotype	**IgG1**
Calculated MW	**146.34 KDa**

Anti-IL-18 Reference Antibody (Camoteskimab) - Additional Information

Target/Specificity
IL-18

Endotoxin
< 0.001EU/ μg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-IL-18 Reference Antibody (Camoteskimab) - Protein Information

Name IL18 (HGNC:5986)

Synonyms IGIF, IL1F4

Function
Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532, PubMed:37993714). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:<a href="http://www.uniprot.org/citations/10653850"

target="_blank">10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744).

Cellular Location
Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed:33883744). In response to inflammasome-activating signals, cleaved and secreted (PubMed:33883744, PubMed:37993712, PubMed:37993714). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744, PubMed:37993714). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059).

Tissue Location
[Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4

Anti-IL-18 Reference Antibody (Camoteskimab) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-IL-18 Reference Antibody (Camoteskimab) - Images



Anti-IL-18 Reference Antibody (Camoteskimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



The purity of Anti-IL-18 Reference Antibody (Camoteskimab)is more than 98.41% ,determined by SEC-HPLC.



Immobilized human IL 18 C His at 2 μg/mL can bind Anti-IL-18 Reference Antibody (Camoteskimab)EC50=0.0126 μg/mL



Anti-IL-18 Reference Antibody (Camoteskimab)-induced FACS Blocking activity was evaluated using Hu IL-18Rα&IL-18Rβ HEK293-. The IC50 was approximately 0.172 μg/mL .